Rx Drug Promotion: Potential Enforcement Worries
Executive Summary
Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.
You may also be interested in...
False Claims Act: US Justice Department Gives Pharma Early Christmas Present
Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.
Insys ‘Reimbursement Unit’ Fraudulently Boosted Fentanyl Rxs, DOJ Charges
Six former Insys executives and managers arrested on changes of misleading insurers and pharmacy benefit managers into authorizing payments for Subsys sublingual fentanyl pain medicine.
Azurity’s Xatmep Promotional Email To Healthcare Professionals Gets Dinged By US FDA
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: